Loading...
NPI 1144981184 · Dallas, TX · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Medshield Labs LLC is a clinical medical laboratory provider located in Dallas, Texas. This profile covers 1 Medicare and 5 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Medshield Labs LLC |
| Address | 9319 Lbj Fwy Ste 102 |
| City | Dallas |
| State | TX |
| ZIP | 75243 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | January 3, 2022 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $31.5M |
| Medicaid | $73K |
MEDSHIELD LABS LLC is operating as a highly specialized clinical laboratory focused on SARS‑CoV‑2 testing, with its Medicare billing dominated by code K1034 (provision of nonprescription self‑administered COVID‑19 tests). The top 3 Medicare codes are reported to account for 100.0% of the provider's Medicare revenue, and K1034 alone is listed with 2.7M claims, $12 avg paid/claim, and $32.2M revenue — a pattern consistent with an operation organized around mass distribution/reporting of COVID‑19 self‑test results.
Revenue concentration is extreme on the Medicare side: precomputed data show the top 3 Medicare codes account for 100.0% of Medicare revenue, indicating near‑total reliance on a very small set of services. That concentration creates material exposure to any policy, reimbursement, or volume changes affecting those specific codes, particularly K1034.
On payer mix, Medicare overwhelmingly dominates this provider's reported public‑payer revenue: lifetime Medicare revenue is $31.5M versus lifetime Medicaid revenue of $73K, making MEDSHIELD effectively single‑payer (Medicare) at scale in these datasets. The disparity in scale suggests the business model and contracting are primarily oriented toward Medicare billing channels rather than Medicaid.
Competitive standing for K1034 on Medicare is nationally exceptional: the provider ranks #4 of 30143 providers (100th percentile; extreme outlier) for that code, signifying it is a major national participant for nonprescription self‑administered COVID‑19 test reporting. The same code is an in‑state outlier on Medicaid as well, where K1034 ranks #1 of 77 providers (100th percentile; extreme outlier), reinforcing that MEDSHIELD is a dominant reporter of that specific test in both datasets.
Medicaid revenue is concentrated but more distributed across multiple COVID‑related NAAT codes: the top 3 Medicaid codes account for 89.5% of Medicaid revenue with U0003 (50.4%), K1034 (21.4%), and U0005 (17.6%) identified as the largest contributors. U0003 and U0005 are characterized in the data as typical, unremarkable volumes in‑state (70th and 64th percentiles respectively), suggesting MEDSHIELD’s Medicaid footprint combines one extraordinary product (K1034) with more typical high‑throughput NAAT activity.
Detailed Medicaid code volumes show smaller absolute dollars but meaningful activity: U0003 has 1.5K claims and $35.9K revenue, U0005 has 1.4K claims and $12.6K revenue, and 87635 appears with 490 claims and $7.4K revenue. Those figures indicate the provider is conducting both high‑throughput nucleic acid testing and nonprescription test reporting for Medicaid, but at volumes and payment levels far below its Medicare activity.
Tenure is short relative to the scale of reported activity: the NPI was enumerated on 2022-01-03 (~4 years ago), indicating rapid scaling to achieve the large reported Medicare volumes in a relatively brief operating window. Rapid growth to national outlier status for a specific code within that timeframe implies focused, high‑volume operational capability for COVID‑19 test handling and reporting.
The data include statistical outlier labels that reinforce operational interpretation: K1034 is explicitly called an "extreme outlier" both nationally (Medicare) and in‑state (Medicaid), while U0003 and U0005 are noted as "typical, unremarkable" state volumes. Those characterizations support a conclusion that MEDSHIELD’s business is highly specialized around one dominant product line (K1034) complemented by routine NAAT testing activity under U0003/U0005.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 2,682,160 | $10 | $32.2M |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 1 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
1 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| K1034 | 1 | 2,490 | 450 | $10 | $117.8K |
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
5 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 1,490 | $20 | $35.9K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 7,630 | $1 | $15.3K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 1,400 | $10 | $12.6K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 490 | $20 | $7.3K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 10 | $10 | $160 |
How this provider's Medicaid billing volume and revenue compare to other Texas providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Texas median
5 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 101 | 340 | 400 | $50 | $553.5K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 93 | 260 | 640 | $20 | $137.2K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 331 | 850 | 260 | $40 | $77.5K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 332 | 340 | 220 | $10 | $24.1K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 1 | 80 | 340 | $1 | $1.5K |
Other providers in the same ZIP code as Medshield Labs LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Daniella Home Health Services, Inc | TX | Home Health Agency | $0 | $22.3M |
| Healing Hands Ministries Inc. | TX | Federally Qualified Health Center (FQHC) | $0 | $17.3M |
| Gracia Home Health Agency Inc. | TX | Home Health Agency | $0 | $13.3M |
| Lakeshore Healthcare Services, Inc. | TX | Home Health Agency | $0 | $11.3M |
| Wilson Hernandez | TX | Radiation Oncology Physician | $2.2M | $0 |
| Imperial Healthcare LLC | TX | Clinical Medical Laboratory | $1.9M | $1.7K |
| Prg Dallas Asc, LLC | TX | Ambulatory Surgical Clinic/Center | $1.8M | $3.3K |
| Dallas Asc, LLC | TX | Ambulatory Surgical Clinic/Center | $599.4K | $0 |
| Madhavi Muppidi | TX | Physical Medicine & Rehabilitation Physician | $593.5K | $0 |
| Todd Spencer | TX | Vascular Surgery Physician | $451.3K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.